<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492739</url>
  </required_header>
  <id_info>
    <org_study_id>VZVinOLTx</org_study_id>
    <nct_id>NCT00492739</nct_id>
  </id_info>
  <brief_title>Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients</brief_title>
  <acronym>VZVinOLTx</acronym>
  <official_title>Induction and Maintenance of Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients: a Retrospective and Prospective Nationwide Study in Switzerland</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Varicella is a vaccine-preventable disease, which can be severe in immunosuppressed children.
      Currently, the (live) vaccine is not recommended in pediatric orthotopic liver transplant
      recipients. Furthermore, protection due to naturally acquired immunity to VZV or
      post-immunization isn't well described in this population.The questions asked are:

        -  What is the influence of the immunosuppression required after orthotopic liver
           transplantation (OLT) on the maintenance of VZV-specific immunity elicited by wild-type
           varicella infection before OLT transplantation?

        -  What is the influence of the immunosuppression required after OLT on VZV-specific
           immunity elicited by varicella immunization before OLT transplantation?

        -  What is the influence of the residual immunosuppression at ≥ 12 months after OLT
           transplantation on the induction of VZV-specific B and T cell responses elicited by VZV
           vaccination after OLT transplantation?

        -  What is the influence of the residual immunosuppression at ≥ 12 months after OLT
           transplantation on the persistence / waning of B and T cell responses elicited by VZV
           vaccination?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      VZV vaccine given to pediatric liver transplant recipients at least one year after
      transplantation if tehy fulfill inclusion criteria and give informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of VZV vaccine in OLTx recipients</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of VZV vaccine in immunosuppressed OLTx recipients</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Liver Disease</condition>
  <condition>Immunosuppression</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>Varicella vaccine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2-3 doses of Varicella vaccine to seronegative patients two months apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination with VZV vaccine</intervention_name>
    <description>Varicella vaccination 2 doses 2 months apart.</description>
    <arm_group_label>Varicella vaccine</arm_group_label>
    <other_name>Varilrix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children either awaiting or recipients of a liver transplantation followed at the
             Children's Hospital of Geneva, Switzerland

          -  If vaccination offered: &gt; 12 months of age

        Exclusion Criteria:

          -  Known wild type varicella exposure within four weeks of the initial vaccine

          -  Immunoglobulins administered within the 5 months preceding the receipt of varicella
             vaccine.

          -  Antiviral agents administered during the preceding 4 weeks

          -  Febrile illness (&gt;38.5°) in the 72 hours before vaccine administration

          -  Chronic aspirin therapy

          -  Any other live vaccinations within four weeks of receipt of varicella vaccine

          -  Female patients in childbearing age will have a pregnancy test at enrollment, and at
             the time of the second vaccine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klara M Posfay-Barbe, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Geneva</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klara M Posfay-Barbe, MD, MS</last_name>
    <phone>+41 22 372 5462</phone>
    <email>Klara.PosfayBarbe@hcuge.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie McLin, MD</last_name>
    <phone>+41 22 3723311</phone>
    <email>Valerie.McLin@hcuge.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital of Geneva (HUG)</name>
      <address>
        <city>Geneva</city>
        <state>GE</state>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klara M Posfay-Barbe, MD, MS</last_name>
      <phone>+41 22 372 5462</phone>
      <email>Klara.PosfayBarbe@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Valerie McLin, MD</last_name>
      <phone>+41 22 372 3311</phone>
      <email>Valerie.McLin@hcuge.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Klara M Posfay-Barbe, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2007</study_first_submitted>
  <study_first_submitted_qc>June 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Klara M. Pósfay Barbe</investigator_full_name>
    <investigator_title>Head of Pediatric Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>Orthotopic liver transplantation</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Varicella vaccine</keyword>
  <keyword>B cell response</keyword>
  <keyword>T cell response</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Varicella</keyword>
  <keyword>Chickenpox</keyword>
  <keyword>transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

